<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847544</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-629-COVID-19-001</org_study_id>
    <nct_id>NCT04847544</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety,&#xD;
      Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment&#xD;
      of COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Safety Assessment Period (Day 1 - 28)</time_frame>
    <description>Adverse Event Collection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale score.</measure>
    <time_frame>Day 1 - 28</time_frame>
    <description>1- 8 Scale (Death - No limitations on activities )</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ADX-629 300 mg administered orally twice daily (BID) for up to 28 days.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo administered orally BID for up to 28 days.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-629</intervention_name>
    <description>ADX-629 administered orally twice daily (BID) for up to 28 days.</description>
    <arm_group_label>ADX-629 300 mg administered orally twice daily (BID) for up to 28 days.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally BID for up to 28 days.</description>
    <arm_group_label>Placebo administered orally BID for up to 28 days.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is a male or female greater than or equal to18 years of age at Screening;&#xD;
&#xD;
          -  Is willing and able to sign and date (or has a legally authorized representative&#xD;
             willing to sign and date) a written (or electronic) informed consent form or provide&#xD;
             equivalent consent per Food and Drug Administration guidelines on COVID-19 clinical&#xD;
             trials;&#xD;
&#xD;
          -  Has a documented, laboratory-confirmed severe acute respiratory syndrome coronavirus-2&#xD;
             (SARS-CoV-2) infection as determined by polymerase chain reaction, a SARS-CoV-2&#xD;
             antigen test, or another commercial or public health assay, within 3 days (72 hours)&#xD;
             of randomization;&#xD;
&#xD;
          -  Has COVID-19 of moderate severity, as defined by the following: Positive testing by&#xD;
             standard reverse transcription polymerase chain reaction assay or equivalent testing;&#xD;
             Symptoms of illness with COVID-19, which could include any of the following: cough,&#xD;
             fever, shortness of breath, chest pain, abdominal pain, nausea/vomiting, diarrhea,&#xD;
             body aches, weakness/fatigue, or new loss of taste or smell; Clinical signs suggestive&#xD;
             of illness with COVID-19, such as respiratory rate greater than or equal to 20 breaths&#xD;
             per minute, saturation of oxygen greater than 93% on room air at sea level, or heart&#xD;
             rate greater than or equal to 90 beats per minute; and No clinical signs indicative of&#xD;
             severe or critical severity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has an NIAID ordinal scale score &lt;5;&#xD;
&#xD;
          -  Is on high-flow oxygen or any form of noninvasive ventilation, excluding continuous&#xD;
             positive airway pressure (CPAP) alone for sleep disorders (e.g., obstructive sleep&#xD;
             apnea);&#xD;
&#xD;
          -  Has significant cardiovascular disease, defined by myocardial infarction, arterial&#xD;
             thromboembolism, or cerebrovascular thromboembolism within 3 months prior to&#xD;
             randomization; symptomatic dysrhythmias or unstable dysrhythmias requiring medical&#xD;
             therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York&#xD;
             Heart Association Class 3 or 4 congestive heart failure; Grade 3 hypertension&#xD;
             (diastolic blood pressure greater than or equal to 100 mmHg or systolic blood pressure&#xD;
             greater than or equal to 160 mmHg); history of congenital prolonged QT syndrome, or&#xD;
             known dyslipidemia;&#xD;
&#xD;
          -  Is currently taking any investigational products, other than the study drug;&#xD;
&#xD;
          -  Has any other condition that, in the opinion of the Investigator, could interfere with&#xD;
             (or for which the treatment might interfere with) the conduct of the clinical trial or&#xD;
             interpretation of the clinical trial results or that would place the subject at undue&#xD;
             risk by participating in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Research Center of Miami II, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Perez, MD</last_name>
      <phone>305-882-1100</phone>
      <email>carlos.perez@medicalinvestigations.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

